By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia today announced that insurer Humana will provide reimbursement for the firm's MammaPrint breast cancer recurrence test.

The Dutch molecular diagnostics firm said that the contract with Humana will expand coverage for MammaPrint by more than 17 million lives. Coding guidelines for the test were established in November 2009 by Palmetto GBA, California's Part B Medicare administrator.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.